Back to overview

Pharmacologic Treatment of Eosinophilic Esophagitis

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author Schoepfer Alain M., Straumann Alex, Safroneeva Ekaterina,
Project Defining clinically meaningful therapeutic endpoints in Eosinophilic Esophagitis
Show all

Original article (peer-reviewed)

Journal Gastrointestinal Endoscopy Clinics of North America
Volume (Issue) 28(1)
Page(s) 77 - 88
Title of proceedings Gastrointestinal Endoscopy Clinics of North America
DOI 10.1016/j.giec.2017.07.007


Eosinophilic esophagitis (EoE) is defined as a chronic, immune-medicated or antigen-mediated, esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Food allergens are identified in most patients. Treatment strategies include elimination diets, drugs, and esophageal dilation. This article focuses on pharmacologic treatment. Currently, there is no pharmacologic treatment that has been approved by regulatory authorities. Established pharmacologic options to treat EoE include proton pump inhibitors and swallowed topical steroids. Several biologic therapies are currently under evaluation and some of them have shown promising results in improving biologic endpoints and patient-reported outcomes.